|
WO2021029385A1
|
|
Oncolytic vaccinia virus
|
|
WO2021020576A1
|
|
Tissue fibrosis inhibitor in which biocompatible polymer is used
|
|
WO2020175660A1
|
|
Rsv f/g chimeric vaccine
|
|
WO2020121983A1
|
|
Vaccine for preventing or treating congenital infection with cytomegalovirus
|
|
WO2020085457A1
|
|
Modified cmv gb protein and cmv vaccine including same
|
|
WO2019044927A1
|
|
Modified hsv gb protein and hsv vaccine including same
|
|
EP3677677A1
|
|
Anti-hsv gb monoclonal antibody or antigen-binding fragment thereof
|
|
CN111051333A
|
|
Modified HSV gD protein and vaccine containing same
|
|
JP2019187249A
|
|
Processes for producing poxvirus using proliferative helper vaccinia virus
|
|
EP3530285A1
|
|
METHOD FOR PRODUCING Hib CONJUGATE VACCINE USING LOW MOLECULAR WEIGHT PRP
|
|
MX2016013819A
|
|
Prophylactic vaccine against egg drop syndrome (eds).
|
|
EP2829281A1
|
|
Lps vaccine
|
|
EP2441477A1
|
|
Wound-covering material
|
|
AU2008202374A1
|
|
Genetically modified ecarin and process for producing the same
|
|
AU2005205314A1
|
|
Process for producing human serum albumin by heating in presence of divalent cation
|
